--- canonical_url: https://www.stockexpertai.com/earnings/dhr last_updated: 2026-05-03T21:32:47.901Z --- # Danaher Corporation (DHR) Q4 FY2026 Earnings Preview > This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-03T21:32:46.721Z. Educational tool, not investment advice. --- ## Quick Summary | Field | Value | Source | |---|---|---| | Price | $175.15 (▼ -2.12%) | fmp:quote | | Market Cap | $124.0B | fmp:profile | | 52w range | $174.60 – $242.80 | fmp:quote | | Earnings | Tue 28 Jul | fmp:earnings-history | | EPS estimate | $1.85 (+3% YoY) | fmp:earnings-estimate | | Revenue estimate | $6.1B | fmp:earnings-estimate | | Beat streak | 5/4 | fmp:earnings-history | | Rating | B (overall 3/5) | fmp:ratings | | Analyst median target | $249 (+42.2% upside) | fmp:price-target-consensus | | MoonshotScore | 51/100 | derived | | Council | 3/6 bullish | derived | | Munger verdict | Undervalued | derived | ## Danaher Corporation — Q4 FY2026 Expectations Q4 consensus: revenue $6.1B^{[FMP est]}, EPS $1.85^{[FMP est]}. 5 consecutive quarters of beat^{[FMP earnings]}. ## Quick Take **Score:** B · **Stance:** BUY · **Council:** 3/6 · **Moonshot:** 51 = MoonshotScore 51^{[9-pillar formula]} + Council 3/6^{[6-lens rule]}. Form 4: 0 transactions^{[FMP Form 4]}. ## Watchlist (4 metrics) ### 1. Fy26 Eps Guidance Danaher is raising its full year 2026 adjusted diluted net EPS guidance to a range of $8.35 to $8.55 versus its previous range of $8.35 to $8.50, given their strong Q1 performance. > "Additionally, given our strong Q1 performance, we're raising our full year adjusted diluted net EPS guidance to a range of $8.35 to $8.55 versus our previous range of $8.35 to $8.50." > — Rainer Blair, President and Chief Executive Officer, Expectation / Guide · Q1 FY2026 ### 2. Fy26 Core Revenue Guidance For the full year 2026, Danaher maintains its expectation of core revenue growth in the 3% to 6% range. > "For the full year 2026, there is no change to our expectation of core revenue growth in the 3% to 6% range." > — Rainer Blair, President and Chief Executive Officer, Expectation / Guide · Q1 FY2026 ### 3. Cepheid Nonrespiratory Growth Cepheid's core nonrespiratory test menu was up mid-teens, led by our 20% growth in sexual health and hospital-acquired infection assays. > "Cepheid's core nonrespiratory test menu was up mid-teens, led by our 20% growth in sexual health and hospital-acquired infection assays." > — Rainer Blair, President and Chief Executive Officer, Investor Focus · Q1 FY2026 ### 4. Bioprocessing Equipment Orders Bioprocessing equipment orders grew more than 30%, marking the first quarter of year-over-year equipment order growth in nearly 2 years. > "Equipment declined modestly in Q1, but we were encouraged to see orders growth of more than 30%, marking the first quarter of year-over-year equipment order growth in nearly 2 years." > — Rainer Blair, President and Chief Executive Officer, Investor Focus · Q1 FY2026 ## MoonshotScore Pillars | Pillar | Score | Level | Evidence | |---|---|---|---| | Revenue Growth | 0.0 | weak | Q1 vs Q2: growth slowing (+0.3%, below threshold) | | Gross Margin | 6.0 | medium | Q1: high margin (60.3%) | | Operating Leverage | 2.0 | weak | op margin healthy (22.6%) | | Cash Runway | 10.0 | strong | FCF very strong ($1.1B, 4.6× CapEx) | | R&D Intensity | 5.0 | medium | average R&D (6.5%) | | Price Momentum | 4.0 | medium | RSI 32.1 weak momentum, 50d below | | News Sentiment | 9.0 | strong | strong buy consensus (92%) | **Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula. ## Council (7-Lens) | Name | Stance | Context | |---|---|---| | Ray Dalio | bull | macro · target upside +42.2% | | Ken Griffin | bear | flow · 50d MA below | | Jim Simons | neutral | quant · RSI 32 | | Klarman | bull | value · target upside +42.2% | | Buffett | neutral | quality · ROE score 3/5 | | Munger | bull | valuation · target upside +42.2% | **Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr. ## Munger Lens - **Verdict:** Undervalued - **Financial Health:** Moderate - **Margin of Safety:** Strong - **Interest Coverage:** Adequate - **ROIC vs WACC:** Tight **Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget. ## Technical Levels - **RSI(14):** 32.1 — momentum zayıf — oversold yakınında değil ama alıcı baskısı az - **50d MA:** $193 — hisse %9.2 altında — kısa vadeli direnç - **200d MA:** $209 — hisse %16.1 altında — uzun vadeli baskı - **Volume (10d):** -36% ## Past Performance (4 Quarters) | Quarter | EPS Actual | EPS Estimate | Result | Reaction | |---|---|---|---|---| | Q2 FY25 | $1.80 | $1.64 | BEAT | +4.2% | | Q3 FY25 | $1.89 | $1.72 | BEAT | -1.2% | | Q4 FY25 | $2.23 | $2.16 | BEAT | -2.2% | | Q1 FY26 | $2.06 | $1.94 | +6.2% EPS | -5.4% | Q1 (April 21, 2026): EPS $2.06 vs $1.94 est^[FMP], +6.2% beat. D+1 movement: -5.4%^{[FMP D+1]}. Decline despite beat — market reacted to guidance, not numbers. ## 3 Scenarios ### Scenario A · Beat **Q4 EPS > $1.85 + CapEx discipline** Threshold: EPS > $1.85^{[FMP est]}. Target: Break above median target $249^{[FMP target]}; high target $270^[FMP] upper bound. ### Scenario B · In-Line **EPS ≈ $1.85 + CapEx < $237.0M** Threshold: EPS ≈ $1.85^{[FMP est]}, Q4 CapEx < $237.0M^[FMP]. Target: Consolidation in the band between current $175^[FMP] and median $249^[FMP]. ### Scenario C · Miss **EPS < $1.79 or CapEx ≥ $237.0M** Threshold: EPS < $1.79^{[FMP est×0.97]}. Target: Current $175 below SMA200 $209^[FMP], if rejection continues, $177^[derived] support activates. ## Risk Notes ### Primary segment below threshold Q1: EPS $2.06 vs $1.94 beat^[FMP], stock -5.4% D+1^[FMP]. ### Backlog concentration No RPO/backlog concentration disclosed in Q1 earnings call. ### Insider trading Form 4 data is marked in the table — this page does not generate assumptions for this stock. | Executive | Action | Amount | Date | |---|---|---|---| **Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26 ### CapEx shock Q1 CapEx $237.0M^{[FMP cashflow]}. Q1 op margin 22.6%^{[FMP op margin]} — this level in Q4 is sensitive to CapEx revision risk. ## Wall Street Consensus - **Median target:** $249 (+42.2% upside vs current $175) - **High / Low:** $270 / $205 - **Buy / Hold / Sell:** 22 / 2 / 0 - **Analyst count:** 4 (last quarter), 49 all-time ## Additional Transcript Insights ### 1. fy26_eps_guidance **Claim:** Danaher is raising its full year 2026 adjusted diluted net EPS guidance to a range of $8.35 to $8.55 versus its previous range of $8.35 to $8.50, given their strong Q1 performance. **Evidence (transcript):** "Additionally, given our strong Q1 performance, we're raising our full year adjusted diluted net EPS guidance to a range of $8.35 to $8.55 versus our previous range of $8.35 to $8.50." **Numbers:** $8.35, $8.55, $8.35, $8.50 ### 2. bioprocessing_equipment_orders **Claim:** Bioprocessing equipment orders grew more than 30%, marking the first quarter of year-over-year equipment order growth in nearly 2 years. **Evidence (transcript):** "Equipment declined modestly in Q1, but we were encouraged to see orders growth of more than 30%, marking the first quarter of year-over-year equipment order growth in nearly 2 years." **Numbers:** 30%, 2 ### 3. masimo_acquisition **Claim:** Danaher expects the Masimo acquisition to be accretive to adjusted diluted net earnings per common share in the first full year post acquisition and to deliver high single-digit return on invested capital by the fifth full year of their ownership. **Evidence (transcript):** "We expect Masimo to be accretive to adjusted diluted net earnings per common share in the first full year post acquisition and to deliver high single-digit return on invested capital by the fifth full year of our ownership." **Numbers:** — ### 4. cepheid_nonrespiratory_growth **Claim:** Cepheid's core nonrespiratory test menu was up mid-teens, led by our 20% growth in sexual health and hospital-acquired infection assays. **Evidence (transcript):** "Cepheid's core nonrespiratory test menu was up mid-teens, led by our 20% growth in sexual health and hospital-acquired infection assays." **Numbers:** 20% ### 5. biotech_china_growth **Claim:** In China, better-than-expected growth in Biotechnology and Life Sciences more than offset the expected high single-digit decline in Diagnostics. **Evidence (transcript):** "In China, better-than-expected growth in Biotechnology and Life Sciences more than offset the expected high single-digit decline in Diagnostics, which continued to be impacted by volume-based procurement and reimbursement policy changes." **Numbers:** — ### 6. fy26_core_revenue_guidance **Claim:** For the full year 2026, Danaher maintains its expectation of core revenue growth in the 3% to 6% range. **Evidence (transcript):** "For the full year 2026, there is no change to our expectation of core revenue growth in the 3% to 6% range." **Numbers:** 3%, 6% --- *Data source: FMP (live query, 2026-05-03), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*